Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714512 | 0.84 | AR (0.56) | ARRPS6KB1AKT1 | |
| SCHEMBL3604536 | 0.83 | AR (0.47) | ARRPS6KB1AKT1DPP4 | |
| SCHEMBL4880027 | 0.83 | AR (0.53) | ARRPS6KB1AKT1DPP4 | |
| Hydrochloric Acid SCHEMBL4881079 | 0.83 | AR (0.55) | ARRPS6KB1AKT1 | |
| SCHEMBL4723950 | 0.81 | AR (0.48) | ARDPP4 | |
| SCHEMBL3599646 | 0.81 | AR (0.62) | AR | |
| SCHEMBL4876287 | 0.81 | AR (0.62) | ARRPS6KB1 | |
| SCHEMBL3615730 | 0.81 | AR (0.62) | AR | |
| SCHEMBL3610108 | 0.81 | AR (0.62) | AR | |
| Hydrochloric Acid SCHEMBL3607071 | 0.80 | AR (0.60) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | AR 1/4885PIK3CD 4051/4885PIK3R1 2371/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | AR 1/4885PIK3CD 3962/4885PIK3R1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.